HANSA BIOPHARMA

Conference Call Presentation

Year-end report January – December 2023

Lund, February 2, 2024

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Hansa enters 2024 in a strong position to successfully execute on our key priorities

1 Q4: Strong commercial performance

- ✓ **Strong revenue generation in Q4 2023**
  - SEK 43m in Idefirix product sales
  - Growth supported by U.K., Germany, and Spain
- ✓ **Commercial partnership with NewBridge**
  - Covering MENA in kidney transplantation
- ✓ **Market Access for Idefirix® in Slovenia**
- ✓ **Initiated restructuring program**
  - Will provide SEK 75-85m in annual savings

2 Pipeline: Encouraging read-outs across several indications

- ✓ **AMR:** Full data from AMR phase 2 study
- ✓ **GBS:** Positive high-level phase 2 data
- ✓ **Anti-GBM:** Positive momentum continues
- ✓ **HNSA-5487:** Encouraging high-level P1 data
- ✓ **Kidney Transplantation:**
  - ConfIdeS: Randomization completion mid-2024
  - Sustained positive outcomes out to year 5
- ✓ **SRP-9001-104 imlifidase in DMD:**
  - Initiation of phase 1 study mid-December 2023

Key strategic priorities

Commercialize Idefirix® in first indication and markets

1

- Successfully launch Idefirix® in Europe
- Secure FDA approval and launch Idefirix® in the U.S.
- Geographic expansion

Advance our ongoing clinical programs

2

- Achieve approval/ usage of imlifidase in follow-on indications
- Broaden the Idefirix® label beyond kidney transplantation

Expand our IgG-cleaving enzyme technology

3

- Expand IgG-cleaving enzyme technology platform into gene therapy
- Develop next gen IgG-cleaving enzymes for repeat usage

Continued progress against our key launch metrics led by in-market growth

Market Development

7 → -

Medical guidelines implemented on a national level in 7 countries

Market Access

14 → 9

Market access secured in 14 European markets, more recently in Slovenia

Patient Identification

28 → 6

Post Approval Study ~56% into completion

Transplant Center Readiness & Use

~50 → 25

~50 clinics are Idefirix "ready" to treat patients

10 → 8

Ongoing HTA processes in 10 countries incl. Portugal and Switzerland

✓

<u>Eurotransplant:</u>
First patient treated in the ET desensitization program; 1st and 2nd wave patient assessment initiated in Q4'23

23 → 10

23 centers have treated patients overall; 14 centers have repeat usage

Major markets to support growth going forward France, U.K., Germany, Spain and Italy

Q4 2023 Q4 2022

Potential to disrupt transplantation care in the U.S. with imlifidase

ConfIdeS phase 3 trial will further advance potential for imlifidase to address unmet need in desensitization

U.S. ConfIdeS

Phase 3

- Continue enrollment beyond 64 patients
- Currently 104 patients screened and enrolled
- 40 out of 64 targeted patients randomized
- Expansion from 17 to 25 site to accelerate randomization
- Randomization expected to complete mid-2024
- BLA filing in 2025

Involved ConfIdeS sites cover more than 20% of total transplantation volumes in the U.S[1]



[1]Organ Procurement & Transplantation Network, OPTN (2023)

Commercial partnership with NewBridge Pharmaceuticals expands market to Middle East & North Africa (MENA)

The MENA region will be the third region outside Europe where Idefirix is commercialized aimed at enabling kidney transplantation in highly sensitized kidney transplant patients

GCC Transplantation Key Facts

~1,500 kidney transplantations in 2022[1]

It's estimated that 10-15% of patients waiting for a kidney offer are highly sensitized[2,3]

19% / 81% deceased vs living transplantations[1]

NewBridge Pharmaceuticals, HQ in Dubai, UAE

- A regional specialty company with a comprehensive pharmaceutical platform of services and expertise
- Established to in-license and commercialize U.S. FDA or EMA approved innovative therapeutics that address unmet medical needs the MENA regions

Key centers identified in the Gulf Cooperation Council, GCC



1. Transplant Observatory (2023), https://www.transplant-observatory.org/export-database/
2. EDQM. (2020). International figures on donation and Transplantation 2019
3. SRTR Database and individual assessments of allocation systems

Advancing HNSA 5487 – a high potential next-gen enzyme for repeat dosing

HNSA-5487

- Engineered for lower immunogenicity
- Short and long-term interval dosing
- Broad range of indications (prolonged or intermittent IgG-free window)

Broaden the IgG free window

Rapidly cleaves IgG and could potentially create a longer IgG-low period

Address unmet need in autoimmune disease

Powerful 5487 IgG cleaving in combination with humoral inhibitor could result in greater control of disease in variety of autoimmune diseases

Enable re-dosing in gene therapy

Could provide solutions to enable re-dosing in AAV gene therapy and prolonged dosing of oncolytic viruses

Potential indication landscape for HNSA-5487 and reasons to believe



First in Human Study Results

- ✓ Administration was safe and well tolerated
- ✓ PD showed a fast and complete cleavage of IgG to F(ab')$_2$ and Fc-fragments with ascending doses; PK in line with expectations
- ✓ Further analysis around endpoints and immunogenicity to be completed in 2024 incl. selection of lead indication

Strong momentum across the pipeline in areas of high unmet need

Phase 1

HNSA-5487 (Lead from NiceR)

- Encouraging first read-out
- Ongoing collection of immunogenicity data in 2024

Pre-treatment Gene Therapy Duchenne

- Study site activated in Dec'23
- Dosing of first patient imminent

Phase 2

Antibody Mediated Rejection (AMR)

- Primary endpoint met
- Plans to publish in peer-reviewed journal

Guillain-Barré syndrome (GBS)

- Positive high-level data
- Further analysis in 2024 to contextualize efficacy data

ANCA-associated vasculitis

- 10 to be enrolled
- 1/3 into completion

Phase 3

US ConfIdeS Study in kidney

- 104 patients enrolled;
- 40 of 64 patients randomized
- Randomization to complete mid'24

Post Approval Study in kidney

- 50 patients to be enrolled
- 56% into completion
- Study to complete by 2025

Anti-GBM disease

- 50 patients to be enrolled
- 36% into completion
- Complete enrollment in 2025

- Next generation enzymes
- Gene Therapy
- Autoimmune / Allograft
- Transplantation

Strong revenue generation in Q4 2023, including SEK 43m in Idefirix product sales

Product sales improved +113% vs Q4 2022 and +163% vs Q3 2023; Growth driven by uptake in U.K., Spain, Germany





Continued investments in commercialization and R&D activities

SG&A expenses (Q/Q)



R&D expenses (Q/Q)



Operating loss (Q/Q)



SG&A expenses (12M/12M)



R&D expenses (12M/12M)



Operating loss (12M/12M)



With current cash position and projected burn-rate, Hansa's operations are financed into 2025

Operating cash flow (Q/Q)



Operating cash flow (12M/12M)



Cash & short-term investments (Q/Q)



Number of employees (Q/Q)



2023 achievements and upcoming milestones 2024/25

2023

Q4 2023

- ✓ **HNSA-5487 (Lead NiceR candidate):** High-level data readout from Phase 1
- ✓ **Long-term follow-up (Kidney tx):** 5-year data readout
- ✓ **GBS Phase 2:** First data readout
- ✓ **AMR Phase 2:** Full data readout
- ✓ **Sarepta DMD pre-treatment Phase 1b:** Commence clinical study

2024

- **GBS Phase 2:** Outcome of comparative efficacy analysis
- **Genethon Crigler-Najjar Phase 1/2:** Initiate clinical study with imlifidase prior to GNT-0003
- **HNSA-5487 (Lead NiceR candidate):** Further analysis around endpoints to be completed in 2024 incl. lead indication
- **U.S. ConfIdeS (Kidney tx) Phase 3:** Complete randomization
- **Sarepta imlifidase in phase 1b in DMD:** First high level data read-out from phase 1b

2025

- **U.S. ConfIdeS (Kidney tx) Phase 3:** BLA submission
- **Anti-GBM disease Phase 3:** Complete enrolment

Q&A

… at Hansa Biopharma, we envision a world where all patients with rare immunologic diseases can lead long and healthy lives…

Visit our website
hansabiopharma.com



Broad clinical pipeline in transplantation, autoimmune diseases, and gene therapy



[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Contact our Investor Relations and Corporate Affairs team

Contact

Klaus Sindahl

VP, Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Stephanie Kenney

VP, Global Corporate Affairs

Mobile: +1 (484) 319 2802

E-mail: stephanie.kenney@hansabiopharma.com

Calendar and events

Feb 6, 2024 Aktiespararna, Falkenberg

Feb 8, 2024 Frankfurt MidCap Seminar, Frankfurt

Feb 14, 2024 Redeye Cell Therapy & Growth Day, Stockholm

Feb 28, 2024 Ökonomisk Ugebrev Life Science Event, Copenhagen

March 4-5, 2024 TD Cowen Healthcare Conference, Boston

March 6, 2024 Life Sciencedagen, Sahlgrenska Universitetssjukhuset Gothenburg

Mar 20, 2024 Annual Report 2023

April 8-11, 2024 Needham Healthcare Conference (virtual)

April 16-17, 2024 Van Lanschot Kempen Life Science Conference, Amsterdam

Apr 18, 2024 Interim Report for January-March 2024

June 27, 2024 2024 Annual General Meeting

July 18, 2024 Half-year Report January-June 2024

Oct 24, 2024 Interim Report for January-September 2024


HANSA
BIOPHARMA